South Korean Authority Approves Inhaler Use

Vectura Group plc confirms that its partner Sandoz, has received South Korean marketing authorisation for AirFluSal^® Forspiro^®  an innovative inhaler for patients with asthma and chronic obstructive pulmonary disease (COPD), making it the first approval in Asia.

The product was first approved in Denmark on December 18^th, 2013, with subsequent approvals in Germany, Belgium, Sweden, Norway, Hungary, Romania and Bulgaria and the product has now been launched in Denmark and Germany.  The new product offers the proven combination of salmeterol (a long-acting inhaled β2-agonist) and fluticasone (an inhaled corticosteroid) in an inhalation device which has visual control features which help reassure the patient about dosing.

The inhaler was awarded the Red Dot Product Design award in 2011, an internationally recognised quality seal awarded by the Design Zentrum Nordrhein Westfalen in Essen, Germany.  It is displayed in design museums in Essen and Singapore.

South Korea has approved the 50µg-250µg and 50µg-500µg dosage forms for the continuous treatment of patients above 12 years of age with persistent asthma or for symptomatic treatment of COPD.